Thromboembolic Events and Metabolic Hyperhomocysteinemia: Unraveling the Links and Clinical Implications

Anass El Mokri El Mghari. *

Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.

Afaf Elmouhdi

Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.

Meriem Tabat

Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.

Hind Siwane

Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.

Abdenasser Drighil

Faculty of Medicine and Pharmacy of Casablanca, Morocco.

Rachida Habbal

Faculty of Medicine and Pharmacy of Casablanca, Morocco.

*Author to whom correspondence should be addressed.


Thromboembolic events, represents one of the major causes of morbidity and mortality worldwide. While traditional risk factors, are well-established, metabolic hyperhomocysteinemia has emerged as a novel and potentially modifiable risk factor. Elevated levels of homocysteine, have been implicated in the pathogenesis of thromboembolic events, highlighting the importance of recognizing hyperhomocysteinemia in clinical practice. This article explores the relationship between thromboembolic events and Hyperhomocysteinemia by first reporting a case of a 20 years old man admitted to the CHU of Casablanca for a pulmonary embolism and in whom an hyperhomocysteinemia was diagnosed, then we will be highlighting the pathophysiology, clinical implications, and management strategies.

Keywords: Hyperhomocysteinemia, thromboembolic events, pulmonary embolism

How to Cite

El Mghari., Anass El Mokri, Afaf Elmouhdi, Meriem Tabat, Hind Siwane, Abdenasser Drighil, and Rachida Habbal. 2024. “Thromboembolic Events and Metabolic Hyperhomocysteinemia: Unraveling the Links and Clinical Implications”. Asian Journal of Case Reports in Medicine and Health 7 (1):72-78.


Download data is not yet available.


Cattaneo M. Hyperhomocysteinemia and thrombosis. Lipids. 2001;36(S1):S13-26.

Cattaneo M. Hyperhomocysteinemia: a risk factor for arterial and venous thrombotic disease. International Journal of Clinical and Laboratory Research. 1997;27:139-44.

Durand P, Prost M, Blache D. Altérations du métabolisme de l’homocystéine et maladies cardiovasculaires. Rev Fr Laboratoires. 1998;307:33–44.

Ospina-Romero M, Cannegieter SC, den Heijer M, Doggen CJM, Rosendaal FR, Lijfering WM. Hyperhomocysteinemia and risk of first venous thrombosis: the influence of (unmeasured) confounding factors. Am J Epidemiol. 2018;187(7): 1392–400.

RouxA, Sanchez O, Meyer G. Quel bilan de thrombophilie chez un patient atteint de maladie veineuse thromboembolique ? Reanimation. 2008;17(4):355–62.

Veyrat-Durebex C, Blasco H, Crinier J, Vayne C, Emond P, Labarthe F, et al. Investigation of hyperhomocysteinemia. Ann Biol Clin. 2013;71(5):517–25.

Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50:3–32.

Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1:228–257.

Cattaneo M. Hyperhomocysteinemia and Venous Thromboembolism. Seminars in Thrombosis and Hemostasis. 2006;32(7): 716–723.

Katherine A. Hajjar. Homocysteine: a sulph’rous fire. J Clin Invest. 2001;107(6): 663-664.


Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine

Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999;81:165–176.

Kane AE, Sinclair DA, Sirtuins and NAD+ in the development and treatment of metabolic and cardiovascular diseases. Circ. Res. 2018;123:868–885.

Ching-Hou Ma, Yen Chun Chiu, Chin-Hsien Wu, I.-Ming Jou, Yuan-Kun Tu, Ching-Hsia Hung, Pei-Ling Hsieh, Kun-Ling Tsai. Homocysteine causes dysfunction of chondrocytes and oxidative stress through repression of SIRT1/AMPK pathway: A possible link between hyperhomocysteinemia and osteoarthritis, Redox Biology. 2018;15:504-512.

Tripodi A, Chantarangkul V, Lombardi R, Lecchi A, Mannucci PM, Cattaneo M. Multicenter study of homocysteine measurement. Performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost. 2001;85:291–295

Hanson NQ, Eckfeldt JH, Schwinchtenberg K, Aras O, Tsai MY. Interlaboratory variation of plasma total homocysteine measurements: results of three successive homocysteine proficiency testing surveys. Clin Chem. 2002;48:1539–1545.

Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: Scriver CR, Beaudet AL, Sly WS, et al eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill. 1995:1279–1327

Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95: 1777–1782.

Cattaneo M, Zighetti ML, Turner RMet al and the ECAT DVT Study Group. Fasting plasma homocysteine levels do not predict the occurrence of deep-vein thrombosis after elective hip replacement surgery. Neth J Med. 1998;52 (suppl): S21

den Heijer M, Willems HPJ, Blom HJ, Gerrits WBJ, Cattaneo M, Eichinger S, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomised, placebo-controlled, double-blind trial. Blood. 2007; 109(1):139–44.

Melhem A, Desai A, Hofmann MA. Acute myocardial infarction and pulmonary embolism in a young man with pernicious anemia-induced severe hyperhomocysteinemia. Thromb J. 2009; 7:5.

Yap S, Boers GH, Wilcken B, et al. Vascular outcome in patients with homocystinuria due to cystathionine betasynthase deficiency treated chronically: a multicenter obser vational study. Arterioscler Thromb Vasc Biol. 2001;21:2080– 2085.

Wu A, Ying Z, Gomez-Pinilla F. Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J Neurotrauma. 2007;24:1587–1595.

Qureshi SS, Gupta JK, Goyal A, Narayan Yadav H. A novel approach in the management of hyperhomocysteinemia. Med Hypotheses. 2019;129:109245.